



LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTORNEY NO. 06177.105001		SERIAL NO. 11/186,311	FILING DATE July 21, 2005					
APPLICANT Calderari et al.					GROUP 1614			
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
SG	AA	4,695,578	9/22/87	Coates et al.	514	397	11/17/1986	
	AB	4,753,789	6/28/88	Tyers et al.	424	10	6/24/1986	
	AC	4,886,808	12/12/89	King	514	299	3/16/1988	
	AD	4,906,755	3/6/90	Gittos	546	94	6/30/1989	
	AE	4,929,632	5/29/90	Tyers et al.	514	397	4/4/1988	
	AF	4,937,247	6/26/90	King	514	299	9/25/1987	
	AG	5,011,846	4/30/91	Gittos et al.	514	294	5/16/1990	
	AH	5,034,398	7/23/91	King	514	299	10/3/1989	
	AI	5,202,333	4/13/93	Berger et al.	514	296	5/22/1991	
	AJ	5,240,954	8/31/93	Tyers et al.	514	395	12/9/1991	
	AK	5,344,658	9/6/94	Collin	424	489	1/19/1993	
	AL	5,578,628	11/26/96	Tyers et al.	514	397	5/30/1990	
	AM	5,578,632	11/26/96	Tyers et al.	514	397	6/7/1995	
	AN	5,622,720	4/22/97	Collin	424	489	6/7/1995	
	AO	5,922,749	7/13/99	Tyers et al.	514	397	8/16/1996	
	AP	5,955,488	9/21/99	Winterborn	514	399	4/28/1998	
	AQ	6,063,802	5/16/00	Winterborn	514	397	1/28/1999	
	AR	2001/0020029	9/6/01	James	514	299	4/13/2000	
↓	AS	6,294,548 B1	9/25/01	James	514	299	4/13/2000	
	SG	AT	2003/0095926 A1	5/22/03	Dugger, III	424	43	8/29/02
	AU							

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE

LIST OF ART CITED BY APPLICANT*(Use several sheets if necessary)*

ATTY. DOCKET NO. 06177.105001		SERIAL NO. 11/186,311		FILING DATE July 21, 2005		
APPLICANT Calderari et al.				GROUP 1614		
FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSLATION YES NO.
SG	AV	WO 03/100091 A	12/4/03	WIPO	Brockmüller	X
	AW					
	AX					
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
SG	AY	Eglen, R. M. et al., <i>Pharmacological Characterization of RS 25259-197, a Novel and Selective 5-HT₃ Receptor Antagonist, in vivo</i> , extracted from <i>British Journal of Pharmacology</i> , 1995, vol. 114, no. 4, pp. 860-66.				
	AZ	Chelly, Jacques et al., <i>Oral RS-25259 Prevents Postoperative Nausea and Vomiting Following Laparoscopic Surgery</i> , extracted from <i>Anesthesiology</i> , 1996, vol. 85, no. 3A, p. A21.				
	BA	Sorbe, Bengt, <i>5-HT₃ Receptor Antagonists as Antiemetic Agents in Cancer Chemotherapy</i> , extracted from <i>Expert Opinion on Investigational Drugs</i> , 1996, vol. 5, no. 4, pp. 389-407.				
	BB	Gaster, Laramie M. and King, Frank D., <i>Serotonin 5-HT₃ and 5-HT₄ Receptor Antagonists</i> , extracted from <i>Medicinal Research Reviews</i> , 1997, vol. 17, no. 2, pp. 163-214.				
	BC	Tang, Jun et al., <i>Efficacy of RS-25259, a Novel 5-HT₃ Antagonist, in the Prevention of Postoperative Nausea and Vomiting After Major Gynecologic Surgery</i> , abstract extracted from <i>Anesthesiology</i> , 1997, vol. 85, no. 3, suppl. p. A329.				
	BD	Tang, Jun et al., <i>The Efficacy of RS-25259, a Long-Acting Selective 5-HT₃ Receptor Antagonist, for Preventing Postoperative Nausea and Vomiting After Hysterectomy Procedures</i> , extracted from <i>Anesthesia and Analgesia</i> , 1998, vol. 87, pp. 462-7.				
	BE	Adis R&D Profile, <i>Palonosetron RS 25259, RS 25259 197</i> , extracted from <i>Drugs in R&D</i> , October 1999, vol. 2, no. 4, pp. 251-52.				
	BF	Piraccini, Gaia et al., <i>An Interesting 5-HT₃ Receptor Antagonist Antiemetic for Patients Undergoing Chemotherapy-Based Conditioning Regimens?</i> , extracted from <i>Blood</i> , Nov. 16, 2001, vol. 98, no. 11, part 2, p. 350b, abstract no. 5169.				
	BG	Stacher, Georg, <i>Palonosetron Helsinn</i> , extracted from <i>Current Opinion in Investigational Drugs</i> , October 2002, vol. 3, no.10, pp. 1502-7.				
SG	BH	Navari, Rudolph M., <i>Pathogenesis-Based Treatment of Chemotherapy-Induced Nausea and Vomiting – Two New Agents</i> , extracted from <i>Journal of Supportive Oncology</i> , 2003, vol. 1(2), pp. 89-103.				
EXAMINER /Shirley Gembeh/				DATE CONSIDERED 08/07/2006		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						